166 related articles for article (PubMed ID: 32317693)
21. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
22. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Létourneau IJ; Quinn MC; Wang LL; Portelance L; Caceres KY; Cyr L; Delvoye N; Meunier L; de Ladurantaye M; Shen Z; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
BMC Cancer; 2012 Aug; 12():379. PubMed ID: 22931248
[TBL] [Abstract][Full Text] [Related]
23. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
24. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
[TBL] [Abstract][Full Text] [Related]
25. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
26. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
Kim O; Park EY; Klinkebiel DL; Pack SD; Shin YH; Abdullaev Z; Emerson RE; Coffey DM; Kwon SY; Creighton CJ; Kwon S; Chang EC; Chiang T; Yatsenko AN; Chien J; Cheon DJ; Yang-Hartwich Y; Nakshatri H; Nephew KP; Behringer RR; Fernández FM; Cho CH; Vanderhyden B; Drapkin R; Bast RC; Miller KD; Karpf AR; Kim J
PLoS Genet; 2020 Jun; 16(6):e1008808. PubMed ID: 32497036
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
[TBL] [Abstract][Full Text] [Related]
28. KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
Stewart ML; Tamayo P; Wilson AJ; Wang S; Chang YM; Kim JW; Khabele D; Shamji AF; Schreiber SL
Cancer Res; 2015 Jul; 75(14):2897-906. PubMed ID: 25968887
[TBL] [Abstract][Full Text] [Related]
29. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
30. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
[TBL] [Abstract][Full Text] [Related]
31. Low-grade Serous Tumors: Are We Making Progress?
Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
[TBL] [Abstract][Full Text] [Related]
32. Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
McCluggage WG; Vosmikova H; Laco J
Int J Gynecol Pathol; 2020 Jan; 39(1):84-92. PubMed ID: 30575604
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract][Full Text] [Related]
34. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract][Full Text] [Related]
35. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
36. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
37. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
38. Combined MEK and BCL-2/X
Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
[TBL] [Abstract][Full Text] [Related]
39. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma.
Khabele D; Fadare O; Liu AY; Wilson AJ; Wass E; Osteen K; Crispens MA
Int J Clin Exp Pathol; 2012; 5(1):37-45. PubMed ID: 22295145
[TBL] [Abstract][Full Text] [Related]
40. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
